H 89 2HCl: Selective PKA Inhibitor for cAMP Pathway Research

Executive Summary: H 89 2HCl, also known as N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide dihydrochloride, is a highly selective, potent inhibitor of protein kinase A (PKA), with a Ki of 48 nM and exhibits over 10-fold greater selectivity for PKA compared to PKG and more than 500-fold selectivity versus other kinases such as PKC, MLCK, and calmodulin kinase II (APExBIO product information). It enables precise dissection of cAMP-dependent signaling pathways in cellular and biochemical assays. Its use has clarified the role of PKA in processes such as neurite outgrowth and protein phosphorylation modulation. H 89 2HCl is widely adopted in neurobiology and kinase research due to its robust activity profile and well-characterized solubility and storage properties (internal review).

Biological Rationale

Protein kinase A (PKA) is a serine/threonine kinase activated by cyclic AMP (cAMP), regulating gene expression, metabolism, and neuronal plasticity. cAMP/PKA signaling is implicated in numerous physiological and pathological contexts, including neuroinflammatory responses, pain modulation, and synaptic plasticity (Liao et al., 2026). In trigeminal neuralgia models, cAMP-dependent pathways interact with mechanosensitive channels, such as Piezo2, and neuropeptides (CGRP, SP), shaping the neuroinflammatory landscape and mechanical allodynia. Inhibition of PKA has proven relevant for dissecting signal specificity and functional outcomes in these systems (see related article—this article adds practical protocol guidance beyond the pathway focus).

Mechanism of Action of H 89 2HCl

H 89 2HCl is a reversible, ATP-competitive inhibitor of the catalytic subunit of PKA. It binds to the ATP-binding pocket, blocking substrate phosphorylation. The compound displays a Ki of 48 nM for PKA, with approximately 10-fold selectivity over PKG and over 500-fold selectivity for PKA versus kinases such as PKC, MLCK, calmodulin kinase II, and casein kinase I/II (APExBIO). At higher concentrations, H 89 can inhibit other kinases, including S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b, but with notably higher IC50 values. In cellular models, H 89 2HCl dose-dependently suppresses forskolin-induced protein phosphorylation and inhibits neurite outgrowth in PC12D cells without altering total intracellular cAMP levels. Its action allows researchers to distinguish cAMP/PKA-dependent from cGMP/PKG-dependent events, as it selectively blocks cAMP-dependent histone IIb phosphorylation while sparing cGMP-dependent processes (see mechanistic review—this article includes detailed selectivity data and storage advice not present in the referenced review).

Evidence & Benchmarks

• H 89 2HCl exhibits a Ki of 48 nM for PKA, providing strong inhibitory potency in vitro (APExBIO).
• The inhibitor demonstrates ~10-fold selectivity for PKA over PKG and at least 500-fold selectivity versus kinases such as PKC, MLCK, calmodulin kinase II, and casein kinase I/II (APExBIO).
• In PC12D cell assays, H 89 2HCl dose-dependently blocks forskolin-induced protein phosphorylation and neurite outgrowth, confirming its role in cAMP/PKA pathway dissection (APExBIO).
• In the context of trigeminal neuralgia, inhibition of cAMP signaling in vivo alleviates mechanical allodynia, supporting the utility of PKA inhibition for mechanistic studies (Liao et al., 2026).
• H 89 2HCl is highly soluble in DMSO (≥51.9 mg/mL), but insoluble in water and ethanol, necessitating careful vehicle selection for experimental use (APExBIO).

Applications, Limits & Misconceptions

H 89 2HCl is widely employed to dissect cAMP/PKA-dependent signaling in neurobiology, cancer, bone, and cell signaling research. It is critical for distinguishing PKA-mediated protein phosphorylation from pathways regulated by PKG or PKC (see translational application guide—the present article offers more detail on selectivity and solubility characteristics). In trigeminal neuralgia models, PKA inhibition by H 89 2HCl serves as a tool to parse the contributions of cAMP/PKA versus PKC in modulating Piezo2, CGRP, and SP expression (Liao et al., 2026).

Common Pitfalls or Misconceptions

• H 89 2HCl is not absolutely specific for PKA at concentrations above 10 μM; higher doses may inhibit S6K1, MSK1, and other kinases.
• It does not reduce intracellular cAMP levels directly; it blocks downstream PKA activity without affecting cAMP synthesis.
• It is not suitable for water- or ethanol-based applications due to solubility limitations; DMSO is required as a vehicle.
• Long-term storage of H 89 2HCl solutions is not recommended, as stability is compromised; fresh preparation is advised.
• Because some processes involve both PKA and PKC, H 89 2HCl alone may not fully distinguish between overlapping signaling pathways.

Workflow Integration & Parameters

H 89 2HCl is typically used in cell-based assays at final concentrations of 30–50 μM, with dosing tailored to the pathway of interest (APExBIO). For in vivo or ex vivo models, pilot dosing and vehicle control optimization are essential. Shipping with blue ice and storage at -20°C preserve compound integrity.

Protocol Parameters

• Stock solution preparation: Dissolve at ≥51.9 mg/mL in DMSO; avoid water or ethanol due to insolubility.
• Working concentration (cellular assays): 30–50 μM; titrate based on cell type and endpoint.
• Storage conditions: Store solid at -20°C; use solutions promptly after preparation.
• Vehicle controls: Always include matched DMSO controls to distinguish vehicle effects.
• Shipping: Ship with blue ice to maintain stability during transit.

Conclusion & Outlook

H 89 2HCl from APExBIO remains a gold-standard tool for probing cAMP/PKA signaling specificity across a spectrum of research domains, including neuroinflammation and pain biology (H 89 2HCl product page). Its selectivity and well-characterized action profile empower precise mechanistic studies. As demonstrated by Liao et al. (2026) and corroborated by multiple internal reviews, PKA inhibition via H 89 2HCl is instrumental in elucidating the molecular underpinnings of mechanotransduction and neuroinflammation. Ongoing research will continue to define the boundaries of PKA involvement in disease models, supported by robust kinase-selective tools such as H 89 2HCl.